DE
News & Events

London (UK), January 15, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company  pioneering a groundbreaking new way of treating cancer, will present its strategy and upcoming milestones to investors in Switzerland on 30 and 31 January, as  it continues to develop its pipeline of oncologic and onco-dermatologic drug candidates to help patients with diseases such as Actinic Keratosis (AK), Cutaneous T-Cell Lymphoma (CTCL), and a wide range of solid tumors.

“Vidac Pharma’s drug candidates offer an entirely new way of treating cancer, by reversing the abnormal metabolism that characterizes all cancer cells. Our drugs harbor the promise of better treatment for patients across a wide range of cancers, possibly in combination with other treatments, and offer a substantial commercial opportunity,” said Prof. Max Herzberg, CEO of Vidac Pharma, and one of the founding fathers of Israel’s life science industry.

During the meetings, Prof. Dr. Thomas Dirschka, one of the world’s pre-eminent experts in AK, and the founder of CentroDerm GmbH, a world-leading dermatology research institute based in Germany, will participate to discuss Vidac Pharma’s innovative approach, which has the potential to significantly improve treatment for cancer patients.

For more information please contact:

Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/

investors@vidacpharma.com
+972-54-4257381
+972-77-9300647

Cohesion Bureau
Giovanni Ca’Zorzi
Investor Relations
giovanni.cazorzi@cohesionbureau.com

Sophie Baumont

Media Relations 

sophie.baumont@cohesionbureau.com

 

About Vidac Pharma

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma was proven effective against advanced Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL) in Phase 2 trials in humans.
www.vidacpharma.com

About CentroDerm

CentroDerm GmbH, headed by Prof. Thomas Dirschka and Dr. Lutz Schmitz, is a specialized treatment facility in the field of dermatology with a private dermatological practice, a surgical treatment facility with a high-end equipped dermatological surgery area, a dermatological laser center with twelve different state-of-the-art skin lasers, a dermato-histological laboratory, a molecular biology laboratory, and a clinical study center. Prof Dirschka has years of expertise in dermatology and has authored numerous publications and textbooks on the topic.
www.centroderm.de

Important information

The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.